209 related articles for article (PubMed ID: 25461323)
21. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.
Huang S; Li R; Connolly PJ; Xu G; Gaul MD; Emanuel SL; Lamontagne KR; Greenberger LM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6063-6. PubMed ID: 16979339
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
Wang R; Zhang X; Song H; Zhou S; Li S
Bioorg Med Chem Lett; 2014 Sep; 24(17):4304-7. PubMed ID: 25127868
[TBL] [Abstract][Full Text] [Related]
24. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
25. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
Abou-Seri SM; Eldehna WM; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 Jan; 107():165-79. PubMed ID: 26590508
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Garofalo A; Farce A; Ravez S; Lemoine A; Six P; Chavatte P; Goossens L; Depreux P
J Med Chem; 2012 Feb; 55(3):1189-204. PubMed ID: 22229669
[TBL] [Abstract][Full Text] [Related]
27. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties.
Conesa-Milián L; Falomir E; Murga J; Carda M; Marco JA
Eur J Med Chem; 2019 May; 170():87-98. PubMed ID: 30878834
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
[TBL] [Abstract][Full Text] [Related]
29. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
Xi L; Zhang JQ; Liu ZC; Zhang JH; Yan JF; Jin Y; Lin J
Org Biomol Chem; 2013 Jul; 11(26):4367-78. PubMed ID: 23715382
[TBL] [Abstract][Full Text] [Related]
30. Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance.
Zha GF; Qin HL; Youssif BGM; Amjad MW; Raja MAG; Abdelazeem AH; Bukhari SNA
Eur J Med Chem; 2017 Jul; 135():34-48. PubMed ID: 28431353
[TBL] [Abstract][Full Text] [Related]
31. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
[TBL] [Abstract][Full Text] [Related]
32. Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities.
Jaballah MY; Serya RAT; Saad N; Khojah SM; Ahmed M; Barakat K; Abouzid KAM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1573-1589. PubMed ID: 31852269
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
[TBL] [Abstract][Full Text] [Related]
34. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
[No Abstract] [Full Text] [Related]
35. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
[TBL] [Abstract][Full Text] [Related]
36. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
37. Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
Peng FW; Wu TT; Ren ZW; Xue JY; Shi L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5137-41. PubMed ID: 26475519
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
[TBL] [Abstract][Full Text] [Related]
39. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
